Niezróżnicowany mięsak pleomorficzny
Charakterystyka, pielęgnacja i opieka

Niezróżnicowany mięsak pleomorficzny (UPS) to agresywny nowotwór tkanek miękkich, stanowiący około 10% mięsaków u dorosłych, najczęściej lokalizujący się w kończynach i jamie brzusznej. Charakteryzuje się znacznym pleomorfizmem komórkowym i brakiem specyficznej linii różnicowania, z szybkim wzrostem i tendencją do przerzutów, zwłaszcza do płuc. Podstawą leczenia jest chirurgia z szerokim wycięciem guza, dążąca do uzyskania ujemnych marginesów (co najmniej 1-2 cm zdrowej tkanki), z możliwością oszczędzania kończyny. Radioterapia, stosowana neoadiuwantowo lub adiuwantowo, wykorzystuje zaawansowane techniki takie jak IMRT czy IORT, poprawiając kontrolę miejscową. Chemioterapia oparta na antracyklinach, gemcytabinie i docetakselu jest stosowana w leczeniu nawrotów, przerzutów oraz przed- i pooperacyjnie. Immunoterapia z pembrolizumabem, szczególnie w skojarzeniu z radioterapią i chirurgią, wykazuje obiecujące wyniki w poprawie przeżycia wolnego od choroby u pacjentów z UPS kończyn w stadium III.

Wprowadzenie do niezróżnicowanego mięsaka pleomorficznego

Niezróżnicowany mięsak pleomorficzny (UPS) to rzadki, agresywny typ nowotworu wywodzący się z tkanek miękkich. Wcześniej znany był jako złośliwy włóknisty histiocytoma (MFH). Charakteryzuje się znacznym pleomorfizmem komórkowym i brakiem specyficznej linii różnicowania. UPS stanowi około 10% wszystkich mięsaków tkanek miękkich u dorosłych, co czyni go jednym z najczęstszych podtypów12.

Nowotwór ten najczęściej występuje w kończynach (zwłaszcza w udach), ramionach lub jamie brzusznej, choć może rozwijać się w dowolnej tkance miękkiej lub kości w całym ciele. Jest to wysoko złośliwy nowotwór, który szybko rośnie i często rozprzestrzenia się do innych części ciała, szczególnie do płuc12.

UPS dotyka najczęściej osoby starsze, ale może wystąpić w każdym wieku. Ze względu na agresywny charakter tego nowotworu, wczesne rozpoznanie i rozpoczęcie leczenia ma kluczowe znaczenie dla rokowania pacjenta1.

Multidyscyplinarne podejście do opieki

Niezróżnicowany mięsak pleomorficzny jest rzadkim nowotworem, który wymaga kompleksowej i wyspecjalizowanej opieki. Leczenie powinno być prowadzone przez doświadczony zespół specjalistów, najlepiej w akademickim lub wielospecjalistycznym centrum onkologicznym12.

Podstawą skutecznego leczenia UPS jest multidyscyplinarny zespół składający się z różnych specjalistów, w tym12:

  • Onkologów chirurgicznych
  • Onkologów ortopedycznych
  • Onkologów klinicznych
  • Radioterapeutów
  • Patologów
  • Radiologów interwencyjnych
  • Radiologów układu mięśniowo-szkieletowego
  • Chirurgów plastycznych
  • Pielęgniarek-nawigatorów

12

Współpraca między różnymi specjalistami pozwala na opracowanie kompleksowego planu leczenia dostosowanego do indywidualnych potrzeb pacjenta. Każdy specjalista pełni określoną rolę, ale wszyscy pracują razem, aby zapewnić najlepszą możliwą opiekę1.

Rola pielęgniarki-nawigatora

Ważnym członkiem zespołu opieki jest pielęgniarka-nawigator, która pełni kluczową funkcję w koordynacji całego procesu leczenia. Do jej zadań należy12:

  • Pomoc pacjentowi w zrozumieniu, czego może oczekiwać podczas leczenia
  • Odpowiadanie na pytania pacjenta i jego rodziny
  • Koordynacja wizyt u różnych specjalistów
  • Ułatwianie komunikacji między członkami zespołu leczącego
  • Organizacja rehabilitacji, wsparcia duchowego, poradnictwa żywieniowego i wsparcia finansowego
  • Monitorowanie stanu pacjenta podczas okresów obserwacji po leczeniu

12

Chirurgiczne metody leczenia

Chirurgia pozostaje główną metodą leczenia niezróżnicowanego mięsaka pleomorficznego, szczególnie we wczesnych stadiach choroby. Celem zabiegu chirurgicznego jest całkowite usunięcie guza wraz z marginesem zdrowych tkanek12.

Operacje oszczędzające kończynę

W przeszłości mięsaki kończyn często leczono przez amputację całej lub części kończyny. Obecnie jednak w większości przypadków można zastosować operacje oszczędzające kończynę (limb-sparing lub limb-salvage surgery)12.

Celem takiej operacji jest usunięcie całego guza wraz z co najmniej 1-2 cm zdrowej tkanki wokół niego (tzw. margines), aby upewnić się, że nie pozostały żadne komórki nowotworowe. Procedura ta nazywana jest szerokim wycięciem (wide excision)1.

Nawet jeśli guz nacieka określone naczynia krwionośne lub nerwy, doświadczony chirurg specjalizujący się w leczeniu mięsaków może w większości przypadków uratować kończynę pacjenta1.

Marginesy chirurgiczne

Kluczowym aspektem operacji jest uzyskanie ujemnych marginesów, co oznacza, że w badaniu histopatologicznym widoczna jest zdrowa tkanka między brzegiem guza a brzegiem wyciętego preparatu1.

Idealnie byłoby uzyskać margines o szerokości co najmniej kilku milimetrów. Jednak w przypadku operacji oszczędzających kończynę, gdy guz przylega do naczynia krwionośnego lub nerwu, chirurg może zastosować minimalny margines, czasami nazywany „planowanym marginesem dodatnim”, który polega na wycięciu cienkiej warstwy, takiej jak przydanka naczynia lub osłonka nerwu1.

Amputacja

W niektórych przypadkach amputacja może być jedynym sposobem na całkowite usunięcie nowotworu lub najlepszą opcją, jeśli usunięcie guza spowodowałoby utratę funkcji kończyny lub przewlekły ból z powodu uszkodzenia kości lub tkanki12.

Po amputacji możliwe jest zastosowanie chirurgii rekonstrukcyjnej i protez kończyn, aby pomóc pacjentowi w odzyskaniu funkcji1.

Radioterapia w leczeniu UPS

Radioterapia wykorzystuje wiązki energii o wysokiej mocy, takie jak promienie rentgenowskie lub protony, do niszczenia komórek nowotworowych. Jest często stosowana w leczeniu niezróżnicowanego mięsaka pleomorficznego, szczególnie w przypadku mięsaków kończyn12.

Radioterapia może być stosowana12:

12

Zaawansowane techniki radioterapii

Aby zmaksymalizować dokładność napromieniania i zminimalizować związane z nim szkody, stosuje się zaawansowane techniki radioterapii, takie jak1:

  • Radioterapia z modulacją intensywności wiązki (IMRT) – która wykazała w badaniach optymalne wskaźniki kontroli miejscowej w przypadku mięsaków tkanek miękkich
  • Śródoperacyjna radioterapia (IORT) – podczas której promieniowanie kierowane jest przez nacięcie chirurgiczne na określone miejsce; dawka IORT może być znacznie wyższa niż w przypadku standardowej radioterapii podawanej z zewnątrz ciała1

1

Chemioterapia i leczenie systemowe

Chemioterapia to leczenie wykorzystujące substancje chemiczne do zabijania komórek nowotworowych. Może być podawana w postaci tabletek lub dożylnie12.

W przypadku niezróżnicowanego mięsaka pleomorficznego, chemioterapia jest najczęściej stosowana12:

  • W przypadku nawrotu choroby po początkowym leczeniu
  • Gdy nowotwór rozprzestrzenia się do innych obszarów ciała
  • Przed operacją, aby zmniejszyć guz i ułatwić jego usunięcie
  • Po operacji, aby zniszczyć pozostałe komórki nowotworowe

12

Schematy chemioterapii

Standardowym leczeniem pierwszego rzutu w przypadku miejscowo zaawansowanego lub przerzutowego UPS pozostaje chemioterapia oparta na antracyklinach1. Inne schematy chemioterapii stosowane w leczeniu UPS mogą obejmować1:

  • Gemcytabina
  • Gemcytabina w połączeniu z Taxotere (docetaksel)

1

W przypadku zaawansowanego, nieresekcyjnego UPS, badane są również schematy łączone, takie jak doksorubicyna w połączeniu z pembrolizumabem1.

Immunoterapia w leczeniu UPS

Immunoterapia wykorzystuje układ odpornościowy pacjenta do walki z nowotworem. Komórki nowotworowe mogą wytwarzać białka, które pomagają im ukryć się przed układem odpornościowym. Immunoterapia działa poprzez zakłócenie tego procesu12.

Najnowsze badania wskazują na unikalne cechy UPS, które mogą przyczyniać się do jego większej wrażliwości na inhibitory punktów kontrolnych układu odpornościowego (ICI) w porównaniu z innymi podtypami mięsaków1.

Pembrolizumab w leczeniu UPS

Pembrolizumab (Keytruda), inhibitor punktu kontrolnego PD-1, wykazał skuteczność w leczeniu różnych nowotworów złośliwych, w tym mięsaków tkanek miękkich1.

Badanie Stand Up to Cancer Sarcoma Alliance for Research through Collaboration (SARC) 032 wykazało, że dodanie pembrolizumabu do przedoperacyjnej radioterapii i chirurgii znacząco poprawiło przeżycie wolne od choroby u pacjentów z UPS kończyn w stadium III w porównaniu z samą radioterapią i chirurgią1.

To multimodalne podejście, łączące immunoterapię, radioterapię i chirurgię, zapewnia kompleksową strategię leczenia zarówno miejscowego, jak i systemowego, stanowiąc znaczący postęp w leczeniu tego agresywnego podtypu mięsaka1.

Opieka po zakończeniu leczenia

Po zakończeniu leczenia niezróżnicowanego mięsaka pleomorficznego pacjenci wymagają ścisłego monitorowania przez okres pięciu lat. Obejmuje to regularne badania fizykalne i okresowe badania obrazowe1.

Wielu pacjentów kontynuuje wizyty kontrolne nawet po upływie pięciu lat, choć z mniejszą częstotliwością1.

Rehabilitacja i wsparcie

W okresie obserwacji po leczeniu pacjenci mogą korzystać z1:

  • Fizjoterapii – aby poprawić funkcję kończyn po operacji
  • Poradnictwa duchowego – aby pomóc w radzeniu sobie z emocjonalnymi aspektami choroby
  • Wsparcia żywieniowego – aby zapewnić optymalną dietę podczas rekonwalescencji
  • Wsparcia finansowego – aby pomóc w radzeniu sobie z kosztami leczenia

1

Rokowanie i przeżycie

Rokowanie w przypadku niezróżnicowanego mięsaka pleomorficznego zależy od wielu czynników, w tym stadium choroby w momencie rozpoznania, wielkości guza i obecności przerzutów1.

Według badania z 2019 roku, wskaźnik przeżycia dla niezróżnicowanego mięsaka pleomorficznego wynosi 60% po pięciu latach i 48% po dziesięciu latach1. Wskaźniki przeżycia długoterminowego mogą jednak nie odzwierciedlać najnowszych postępów w leczeniu i mogą zaniżać obecne szanse na przeżycie1.

Jak w przypadku wszystkich nowotworów, wczesne wykrycie i leczenie zwiększają szanse na pomyślne wyniki1.

Czynniki prognostyczne

Niezróżnicowany mięsak pleomorficzny ma lepsze rokowanie, gdy jest diagnozowany wcześnie i ma mały rozmiar1. Ze względu na wysokie ryzyko nawrotu i przerzutów, monitorowanie powinno być prowadzone regularnie przez lata po wycięciu chirurgicznym1.

W przypadku guzów o niskim stopniu złośliwości i małych rozmiarów, resekcja powinna być przeprowadzona z zamiarem wyleczenia. Jednak w przypadku większych guzów UPS wątroby, rokowanie jest często złe niezależnie od interwencji12.

Wsparcie dla pacjenta i rodziny

Diagnoza nowotworu, takiego jak niezróżnicowany mięsak pleomorficzny, może być przytłaczająca. Z czasem pacjenci znajdują sposoby radzenia sobie ze stresem i niepewnością związaną z chorobą nowotworową12.

Edukacja i wiedza

Pacjenci powinni dowiedzieć się wystarczająco dużo o mięsaku, aby móc podejmować decyzje dotyczące swojej opieki. Warto pytać lekarza o swój mięsak, dostępne opcje leczenia i, jeśli pacjent sobie tego życzy, rokowanie. Im więcej pacjent wie o niezróżnicowanym mięsaku pleomorficznym, tym bardziej pewny siebie może być w podejmowaniu decyzji dotyczących leczenia12.

Wsparcie bliskich

Utrzymywanie bliskich relacji pomoże pacjentom radzić sobie z diagnozą i implikacjami opieki. Przyjaciele i rodzina mogą zapewnić praktyczne wsparcie, takie jak pomoc w opiece nad domem, gdy pacjent jest w szpitalu. Mogą również służyć jako wsparcie emocjonalne, gdy pacjent czuje się przytłoczony chorobą nowotworową12.

Jak podkreśla jedna z pacjentek po przebytym leczeniu UPS: „Będziesz potrzebować pomocy. Nie ma wstydu w proszeniu o pomoc. Potrzebujemy siebie nawzajem”1.

Problemy w okresie przeżycia

Okres po zakończeniu leczenia może być trudny. Pacjenci mogą doświadczać poczucia winy związanego z przeżyciem (survivor’s guilt) i trudności w powrocie do świata, w którym byli przed chorobą1.

Ważne jest, aby pacjenci pamiętali, że są piękni i mają wszystko, czego potrzebują, aby walczyć z chorobą i dostosować się do życia po leczeniu1.

Badania kliniczne i przyszłość leczenia

Badania kliniczne wykorzystują nowe podejścia do leczenia niezróżnicowanego mięsaka pleomorficznego. Mogą być potrzebne, gdy standardowe leczenie nie jest skuteczne1.

Trwające i przyszłe badania kliniczne powinny kłaść silny nacisk na badania korelacyjne biomarkerów, aby dowiedzieć się więcej o unikalnej biologii UPS i zidentyfikować pacjentów, dla których terapia oparta na inhibitorach punktów kontrolnych układu odpornościowego będzie skuteczna1.

Badanie EA7222

Badanie EA7222 to randomizowane badanie fazy 3 doksorubicyny stosowanej samodzielnie lub w połączeniu z pembrolizumabem u pacjentów z zaawansowanym UPS i pokrewnymi słabo zróżnicowanymi mięsakami, których nie można usunąć chirurgicznie (nieresekcyjnymi)1.

Głównym celem badania jest ocena, czy terapia skojarzona poprawi przeżycie wolne od progresji (PFS) w tej populacji pacjentów1.

Pacjenci przydzieleni losowo do ramienia A otrzymają sześć 3-tygodniowych cykli doksorubicyny plus pembrolizumab, a następnie będą nadal otrzymywać pembrolizumab do progresji, nieakceptowalnych działań niepożądanych lub do zakończenia 2 lat terapii1.

Pacjenci przydzieleni losowo do ramienia B, otrzymujący doksorubicynę, u których nastąpi progresja choroby, będą zachęcani do zmiany leczenia i otrzymywania pembrolizumabu jako pojedynczego środka przez okres do 2 lat1.

Podsumowanie zasad opieki

Opieka nad pacjentem z niezróżnicowanym mięsakiem pleomorficznym wymaga kompleksowego, wielodyscyplinarnego podejścia. Kluczowe zasady opieki obejmują12:

  • Leczenie w wyspecjalizowanym centrum mięsaków z doświadczonym zespołem multidyscyplinarnym
  • Dokładną diagnostykę i właściwe zaplanowanie biopsji
  • Chirurgiczne usunięcie guza z odpowiednimi marginesami
  • Zastosowanie radioterapii przed- lub pooperacyjnej
  • Rozważenie chemioterapii, immunoterapii i terapii celowanych w zależności od stadium choroby
  • Regularne obserwacje po zakończeniu leczenia
  • Kompleksowe wsparcie psychologiczne, fizyczne i społeczne
  • Edukację pacjenta na temat choroby i dostępnych opcji leczenia

12

Wszystkie te elementy przyczyniają się do optymalizacji wyników leczenia i poprawy jakości życia pacjentów z niezróżnicowanym mięsakiem pleomorficznym1.

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 12.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1 Undifferentiated Pleomorphic Sarcoma | Orthopedic Surgery | Patient Care | Montefiore Einstein
    https://montefioreeinstein.org/patient-care/services/orthopedics/specialties/orthopedic-oncology/pleomorphic-sarcoma
    Undifferentiated pleomorphic sarcoma (UPS) is a rare type of cancer that arises in soft tissue. UPS represents about 10 percent of all adult soft-tissue sarcomas, making it one of the most common subtypes. […] Treatment for undifferentiated pleomorphic sarcoma generally involves surgery. When the tumor is small and found in just one part of the body, surgery is sometimes enough and no additional treatments are required. […] If the tumor is larger than five centimeters, the combined use of surgery and radiation therapy offers patients better control of their disease, meaning a lower risk of local recurrence. […] Following the completion of treatment, patients typically require close monitoring for a period of five years. This includes physical examinations and periodic imaging studies. Many patients continue to follow up even after five years, though at a reduced rate.
  • #1 Undifferentiated Pleomorphic Sarcoma | Norton Children’s
    https://nortonchildrens.com/services/cancer/conditions/sarcoma/undifferentiated-pleomorphic-sarcoma/
    Undifferentiated pleomorphic sarcoma is a rare cancer that usually forms in soft tissue in the legs, arms or abdomen, but it can form in any soft tissue or bone anywhere in the body. […] Also called malignant fibrous histiocytoma or undifferentiated sarcoma, this aggressive cancer can grow fast and often spreads to other parts of the body, including the lungs. […] The survival rate for undifferentiated pleomorphic sarcoma is 60% at five years and 48% at 10 years, according to a 2019 study. As with all cancers, early detection improves the survival rate. By their nature, long-term survival rates don’t reflect the latest advancements in treatment and may underestimate current survival chances. […] One of the most common symptoms is a growing lump in the leg that can become painful. The cancer also may be found in the arms and abdomen, or anywhere in the body. Fever and weight loss also can be symptoms. Like many childhood and adolescent cancers, undifferentiated pleomorphic sarcoma can have vague symptoms that can be easily overlooked or attributed to other causes. An accurate diagnosis requires oncologists with skill, experience and knowledge of the latest discoveries. Consulting with a pediatric cancer specialist offers the best opportunity for early diagnosis and successful treatment. […] Undifferentiated pleomorphic sarcoma has the best chance of being cured when it’s treated by pediatric cancer specialists. Young adults may benefit from treatment at a children’s hospital instead of an adult-service hospital because of the care team’s expertise specifically in childhood diseases.
  • #1 Undifferentiated pleomorphic sarcoma – Diagnosis and treatment – Mayo Clinic
    https://www.mayoclinic.org/diseases-conditions/undifferentiated-pleomorphic-sarcoma/diagnosis-treatment/drc-20389565
    Our caring team of Mayo Clinic experts can help you with your undifferentiated pleomorphic sarcoma-related health concerns […] Undifferentiated pleomorphic sarcoma is rare and often requires complex care. It’s best treated by someone who has significant experience with it, which often means an academic or multispecialized cancer center. […] Learn enough about sarcoma to make decisions about your care. Ask your doctor about your sarcoma, including your treatment options and, if you like, your prognosis. As you learn more about undifferentiated pleomorphic sarcoma, you may become more confident in making treatment decisions. […] Keeping your close relationships strong will help you deal with your diagnosis and care implications. Friends and family can provide the practical support you’ll need, such as helping take care of your home if you’re in the hospital. And they can serve as emotional support when you feel overwhelmed by cancer.
  • #1 Undifferentiated pleomorphic sarcoma – Care at Mayo Clinic – Mayo Clinic
    https://www.mayoclinic.org/diseases-conditions/undifferentiated-pleomorphic-sarcoma/care-at-mayo-clinic/mac-20389586
    Mayo Clinic medical oncologists, pathologists and many other specialists work together for undifferentiated pleomorphic sarcoma care. […] At Mayo Clinic, medical oncologists, pathologists, surgical oncologists, radiation oncologists, musculoskeletal radiologists, interventional radiologists and plastic surgeons work as a multidisciplinary team to care for people with undifferentiated pleomorphic sarcoma. […] Mayo Clinic doctors care for more than 2,000 people with soft tissue sarcomas each year, including very rare types. This means your care team is prepared with the knowledge and resources to provide you with exactly the care you need. […] Mayo Clinic doctors have the knowledge and resources to provide comprehensive care for people with rare cancers, including undifferentiated pleomorphic sarcoma.
  • #1 Undifferentiated Pleomorphic Sarcoma: Symptoms & Treatment
    https://my.clevelandclinic.org/health/diseases/22435-undifferentiated-pleomorphic-sarcoma
    Your treatment plan is unique to you. Ask your oncologist about your options. You’ll likely have a multidisciplinary team, including a surgeon, a radiation oncologist and a medical oncologist. Each specialist has a specific role, but they all work together to treat you. They can help you determine what’s best in your situation. […] You should see a healthcare provider right away any time you notice a growing lump or mass especially if it occurs with pain, swelling or limited range of motion. […] If you already know you have UPS, tell your oncologist right away if you develop any new or worsening symptoms. […] It’s possible to cure UPS, especially during the early stages. There still may be treatment options in later stages, which can prolong your quality of life. Like any type of cancer, early detection and treatment increase your chances for successful outcomes. […] Sarcomas are a rare form of cancer affecting your bones and soft tissues. Our specialists use the latest treatments to care for these types of tumors.
  • #1 Soft Tissue Sarcoma Treatment | Sarcoma Care Team | Parkview Health
    https://www.parkview.com/medical-services/cancer/cancers-we-treat/soft-tissue-sarcoma
    Soft tissue sarcomas are a rare group of cancers arising from connective tissue such as muscle, fat, nerves, bone and vascular tissue, that can occur at any age. […] At Parkview Cancer Institute we have a dedicated Sarcoma Care Team including radiation oncology, medical oncology, interventional radiology, pathology, plastic surgery, nurse navigation, genetics, nutrition, spiritual support, and financial support, led by our orthopedic oncologic surgeon. […] To maximize accuracy of radiation and minimize associated harm, we utilize Intensity Modulated Radiation Therapy (IMRT), which has been demonstrated in studies to result in optimal local control rates for soft tissue sarcomas. […] During the surveillance period, patients undergo physical therapy, spiritual counseling, nutritional support, and financial support as needed, all of which is coordinated by our sarcoma nurse navigator.
  • #1 Undifferentiated Pleomorphic Sarcoma: Symptoms & Treatment
    https://my.clevelandclinic.org/health/diseases/22435-undifferentiated-pleomorphic-sarcoma
    Undifferentiated pleomorphic sarcoma treatment depends on the size of the tumor and whether the cancer has spread. The main treatment for early-stage UPS is typically surgery to remove the growth, most often combined with radiation therapy. But you might need additional cancer treatments, too. […] Surgery for undifferentiated pleomorphic sarcoma involves removing the tumor. The goal is to remove the entire sarcoma and a little bit of the healthy tissue around it (known as the margin). Your surgeon does this to improve the chances of removing all the cancer cells. If cancer cells are at the edge of the removed tumor, there’s a risk that some may be left in your body as well. […] Oncologists may also use additional treatments before or after surgery. These treatments rarely shrink the tumor, but they can help make the tumors safer to remove at surgery or treat any remaining cancer cells after surgery: Chemotherapy, Immunotherapy, Radiation therapy.
  • #1 Sarcoma
    https://medschool.cuanschutz.edu/colorado-cancer-center/for-patients-families/cancers-we-treat/sarcoma
    In the past, sarcomas in the arms and legs were often treated by amputating all or part of the limb. Today, most sarcomas of the limbs can be removed without amputation. The goal of limb-sparing or limb-salvage surgery is to remove the entire tumor, along with at least 1 to 2 cm of the normal tissue around it to ensure no cancer cells are left behind. This area of healthy tissue around the tumor is called the margin, and the procedure is called a wide excision. […] […] For bone sarcomas, the section of bone that is removed may be replaced with a piece of bone from another part of the body or from another person (a bone graft) or with a synthetic device (an internal prosthesis). Some devices combine a graft and a prosthesis. […] […] Sometimes, an amputation may be the only way to remove all of the cancer, or it may be the best option if removing the tumor would result in loss of limb function or chronic pain due to bone or tissue damage. Reconstructive surgery and the use of prosthetic (artificial) limbs may be options for patients who undergo amputation to help them regain function afterward. […]
  • #1 Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Surgical Oncology Goals
    https://www.onclive.com/view/moving-the-needle-in-undifferentiated-pleomorphic-sarcoma-surgical-oncology-goals
    Once they’ve undergone their neoadjuvant therapy, we’re going to want to do a resection of the tumor that involves negative margins. What that means is we want to see on the pathology that there is normal tissue between the edge of the tumor and the edge of the specimen. […] Ideally, we’re getting at least a couple of mm, as wide a margin as possible. But when we’re performing limb salvage surgery, these tumors may be pressed up against a blood vessel or a nerve, so we may be taking a very minimal margin, or sometimes what some people call a planned positive margin, which is really when we’re resecting a thin layer, such as the adventitia off a vessel or the epineurium off a nerve, and that’s going to be our margin. […] At this point, most of the time we’re able to save someone’s arm or leg. […] For the most part, someone who specializes in sarcoma can save the person’s extremity the majority of the time. […] Even if the tumor involves certain blood vessels or certain nerves, there are methods to save the patient’s limb.
  • #1 Sarcoma
    https://medschool.cuanschutz.edu/colorado-cancer-center/for-patients-families/cancers-we-treat/sarcoma
    Radiation therapy uses high-energy beams (such as x-rays) to destroy cancer cells. It is used most often for sarcomas of the arms and legs but may also be used for other sarcomas. Radiation may be given before sarcoma surgery (neoadjuvant radiation) to shrink tumors or after surgery (adjuvant radiation) to kill any remaining cancer cells. It is often given in combination with chemotherapy, which is known as chemoradiotherapy or chemoradiation. […] […] Chemotherapy is a drug treatment to kill cancer cells. Some types of sarcomas respond better to chemotherapy than others. Like radiation therapy, chemotherapy may be used before surgery to try to shrink the tumors or after surgery to kill any remaining cancer cells. […] […] Targeted therapies use drugs to inhibit the action of defective genes and slow or halt the growth and spread of sarcoma cancer cells while limiting harm to healthy cells.
  • #1 Mayo Clinic Health Library – Undifferentiated pleomorphic sarcoma | Swiss Medical Network
    https://www.swissmedical.net/en/healtcare-library/con-20344525
    Radiation therapy uses high-powered beams of energy, such as X-rays or protons, to kill cancer cells. […] Chemotherapy is a drug treatment that uses chemicals to kill cancer cells. It can be administered by pill or through a vein (intravenously), or both. […] Chemotherapy is most often used to treat undifferentiated pleomorphic sarcoma that comes back after initial treatment or that spreads to other areas of the body. […] Immunotherapy uses your immune system to fight cancer. Your body’s disease-fighting immune system may not attack your cancer because the cancer cells produce proteins that help them hide. Immunotherapy works by interfering with that process. […] During intraoperative radiation therapy (IORT) radiation is directed through the surgical incision onto a specific site; in this case a thigh. IORT dosage can be much higher than for standard radiation therapy given from the outside of the body.
  • #1 Undifferentiated pleomorphic sarcoma | Health Library | Memorial Health System
    https://www.mhsystem.org/health-library/con-20344525/
    Radiation therapy uses high-powered beams of energy, such as X-rays or protons, to kill cancer cells. Radiation therapy can be given as: […] Chemotherapy is a drug treatment that uses chemicals to kill cancer cells. It can be administered by pill or through a vein (intravenously), or both. […] Chemotherapy is most often used to treat undifferentiated pleomorphic sarcoma that comes back after initial treatment or that spreads to other areas of the body. […] Immunotherapy uses your immune system to fight cancer. Your bodys disease-fighting immune system may not attack your cancer because the cancer cells produce proteins that help them hide. Immunotherapy works by interfering with that process. […] A diagnosis of cancer such as undifferentiated pleomorphic sarcoma can be overwhelming. With time youll find ways to cope with the distress and uncertainty of cancer. Until then, you may find it helps to:
  • #1
    https://scholars.duke.edu/publication/1565285
    Over the last decade in soft tissue sarcoma (STS) research, the shifting landscape towards more precise subtype classification and the increasing study of novel therapeutic strategies has prompted a need to highlight current knowledge of effective subtype specific therapies. Undifferentiated pleomorphic sarcoma (UPS), formerly known as malignant fibrous histiocytoma (MFH), is among the most common subtypes of STS arising in the trunk or extremities of adults. Administration of systemic chemotherapy is the primary management in locally advanced and metastatic UPS. While anthracycline-based chemotherapy continues to be standard of care in this setting, outcomes in locally advanced or metastatic UPS remain poor. Recent studies highlight the unique characteristics of UPS that may contribute to its greater sensitivity to immune checkpoint inhibition (ICI) compared to other STS subtypes. […] Ongoing and future clinical trials should place strong emphasis on correlative biomarker studies to learn more about the unique biology of UPS and to identify patients for whom ICI-based therapy will be effective.
  • #1 Nicole’s Stage 3 Undifferentiated Pleomorphic Sarcoma Story – The Patient Story
    https://thepatientstory.com/patient-stories/sarcoma/soft-tissue/undifferentiated-pleomorphic/nicole-b/
    Nicole shares her stage 3 sarcoma story, a soft tissue subtype known as undifferentiated pleomorphic sarcoma (UPS), and undergoing chemotherapy and a Whipple surgery. […] Treatment: Gallbladder removal surgery (Cholecystectomy), Chemotherapy, Whipple surgery. […] The diagnosis happened, and then he said the procedure that you are going to need is called the Whipple procedure. It is a four- to six-hour surgery. Open surgery of the abdomen, about a nine-inch incision down the abdomen. […] Undifferentiated pleomorphic sarcoma, also called UPS. […] They had sent my tumor to MD Anderson to confirm with them that it was sarcoma because it is so rare. […] I had a CVC, a central venous catheter, put in my chest. […] I started chemotherapy. I had two medications, gemcitabine and a combination of gemcitabine and Taxotere.
  • #1 Now Enrolling: EA7222 for Patients with Advanced Soft Tissue Sarcoma – News from the ECOG-ACRIN Cancer Research Group
    https://blog-ecog-acrin.org/now-enrolling-ea7222-for-patients-with-advanced-soft-tissue-sarcoma/
    The EA7222 study is a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated sarcomas that cannot be removed by surgery (unresectable). […] Early research suggests a potential role for immunotherapy in treating patients with metastatic undifferentiated pleomorphic sarcoma (UPS), representing about 20% of all STS cases. […] The study’s primary objective is to assess whether the combination therapy will improve PFS for this patient population. […] Patients randomized to Arm A will receive six 3-week cycles of doxorubicin plus pembrolizumab, then continue receiving pembrolizumab until progression, unacceptable side effects, or up to completion of 2 years of therapy. […] Patients randomized to receive doxorubicin on Arm B whose cancer progresses will be encouraged to switch and receive pembrolizumab as a single agent for up to 2 years.
  • #1 Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Overview of Paradigm
    https://www.onclive.com/view/moving-the-needle-in-undifferentiated-pleomorphic-sarcoma-overview-of-paradigm
    Undifferentiated pleomorphic sarcoma, or UPS, is a type of high-grade malignant soft tissue tumor thats characterized by significant cellular pleomorphism and the absence of a specific line of differentiation. Historically known as malignant fibrous histiocytoma, it is now classified as undifferentiated pleomorphic sarcoma. UPS typically presents as a rapidly growing mass, often located in the extremities or retroperitoneum. It is known for its aggressive behavior with a high propensity for local recurrence and distant metastases. The diagnosis of UPS is one of exclusion, made after ruling out other specific types of sarcomas through histologic assessment, immunohistochemistry, and molecular genetic studies. […] Recently, immunotherapy, radiation therapy, and surgery are emerging as a growing and promising combination for the treatment of UPS of the extremities. Pembrolizumab [Keytruda], an antiPD-1 immune checkpoint inhibitor, has shown efficacy in various malignancies, including soft tissue sarcomas. The Stand Up to Cancer Sarcoma Alliance for Research through Collaboration [SARC] 032 trial demonstrated that the addition of pembrolizumab to preoperative radiotherapy and surgery significantly improved disease-free survival in patients with stage III UPS of the extremities compared with radiation and surgery alone.
  • #1 Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Overview of Paradigm
    https://www.onclive.com/view/moving-the-needle-in-undifferentiated-pleomorphic-sarcoma-overview-of-paradigm
    The multimodal approach addresses both local and systemic disease control, offering a comprehensive treatment strategy for stage III UPS of the extremities. The combination of pembrolizumab, radiotherapy, and surgery represents a significant advancement in the management of this aggressive sarcoma subtype.
  • #1 High-grade undifferentiated pleomorphic sarcoma in the gluteus with a v-y flap: a case report – WCRJ
    https://www.wcrj.net/article/2238
    Undifferentiated pleomorphic sarcoma (UPS) is rare and affects mainly the elderly. […] The objective is to describe the case of a young patient, with a UPS measuring 14 11.2 8.2 cm, with a 6-month evolution and no metastases. […] An anatomopathological study showed a malignant neoplasm of spindle cells and high-grade pleomorphic sarcoma on immunohistochemistry. […] Neoadjuvant chemotherapy and complete resection of the lesion with subsequent adjuvant radiotherapy were performed. […] Since undifferentiated pleomorphic sarcoma has a better prognosis when diagnosed early and in a small size, it is crucial to immediately recognize and assess any enlarged mass and nodule, even though it is a rare diagnosis. […] Due to the high rate of recurrence and metastasis, monitoring should be carried out regularly for years after surgical excision.
  • #1 Pleomorphic Sarcoma of the Liver; To Cut or Not to Cut? | ACS
    https://www.facs.org/for-medical-professionals/news-publications/journals/case-reviews/issues/v1n3/dishong-pleomorphic/
    Undifferentiated pleomorphic sarcoma (UPS) of the liver, previously referred to as primary malignant fibrous histocytoma (MFH), is a rare entity. […] In the current literature, studies show that immediate surgical intervention can show promising patient outcomes and improved prognosis. […] Surgical palliation in UPS should be based on ones overall health and prognosis as measured by nutritional status, function, and surgical candidacy. […] Low grade, small, UPS of the liver should absolutely be resected with curative intent. However, challenges remain concerning the best course of palliation for those patients with larger UPS of the liver. […] Patient motivation, nutrition and biliary patency weigh heavily on hepatic UPS palliation. […] Palliative surgery has proven to benefit patients that are strong surgical candidates, which is directly correlated with: life expectancy, lifestyle, and overall health.
  • #1 Nicole’s Stage 3 Undifferentiated Pleomorphic Sarcoma Story – The Patient Story
    https://thepatientstory.com/patient-stories/sarcoma/soft-tissue/undifferentiated-pleomorphic/nicole-b/
    I talked with other people in the hospital during my first week or two after I knew I was going to need chemo. I decided that I was going to shave it. […] I went in on December 13th to have the four- to six-hour procedure done. When I woke up, my husband said that I was cancer-free and had only been back there for two hours. […] I have a nine-inch incision in my abdomen. […] It is difficult in survivorship. It is a different type of challenge — between survivor’s guilt and trying to submerge yourself back into the world you were in before. […] You will need help. […] There is no shame in asking for help. We need one another. […] You are absolutely beautiful, and you will have everything you need to fight this.
  • #1 Undifferentiated Pleomorphic Sarcoma
    https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/uncertain-differentiation-undifferentiated-pleomorphic-sarcoma/
    Radiation therapy is used to kill or shrink tumor cells using high-energy radiation beams. […] Chemotherapy uses strong medication to stop the growth of tumor cells. […] Clinical trials use new treatment approaches for uncertain differentiation sarcomas. You may need clinical trials or more cutting-edge personalized treatments when standard treatments are not effective. […] The treatment plan for this type of sarcoma is based on the tumor stage, prior treatments (if any), growth of the tumor, and biopsy analysis. […] At our office in Santa Monica, we design personalized and innovative plans for treating skeletal muscle sarcoma.
  • #2 Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Overview of Paradigm
    https://www.onclive.com/view/moving-the-needle-in-undifferentiated-pleomorphic-sarcoma-overview-of-paradigm
    Undifferentiated pleomorphic sarcoma, or UPS, is a type of high-grade malignant soft tissue tumor thats characterized by significant cellular pleomorphism and the absence of a specific line of differentiation. Historically known as malignant fibrous histiocytoma, it is now classified as undifferentiated pleomorphic sarcoma. UPS typically presents as a rapidly growing mass, often located in the extremities or retroperitoneum. It is known for its aggressive behavior with a high propensity for local recurrence and distant metastases. The diagnosis of UPS is one of exclusion, made after ruling out other specific types of sarcomas through histologic assessment, immunohistochemistry, and molecular genetic studies. […] Recently, immunotherapy, radiation therapy, and surgery are emerging as a growing and promising combination for the treatment of UPS of the extremities. Pembrolizumab [Keytruda], an antiPD-1 immune checkpoint inhibitor, has shown efficacy in various malignancies, including soft tissue sarcomas. The Stand Up to Cancer Sarcoma Alliance for Research through Collaboration [SARC] 032 trial demonstrated that the addition of pembrolizumab to preoperative radiotherapy and surgery significantly improved disease-free survival in patients with stage III UPS of the extremities compared with radiation and surgery alone.
  • #2 Undifferentiated Pleomorphic Sarcoma
    https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/uncertain-differentiation-undifferentiated-pleomorphic-sarcoma/
    Undifferentiated pleomorphic sarcoma is a malignant sarcoma that grows quickly and spreads to other parts of the body, including the lungs. […] The treatment for uncertain differentiation sarcoma comprises a personalized multimodal approach. It often combines standard treatments, such as surgery and radiation therapy, with new types of treatment, like clinical trials and targeted therapy. […] At Sarcoma Oncology Center, our team collaborates with surgeons, radiologists, and radiation oncologists from prominent institutions to ensure our patients receive personalized attention. […] The following treatment options may be considered for treating uncertain differentiation sarcomas. […] Surgery is used to remove the tumor cells from the body. However, in cases where the tumor cells invade the surrounding tissue and vital organs, it may not be possible to remove all tumor cells by surgery.
  • #2 Undifferentiated pleomorphic sarcoma | Health Library | Memorial Health System
    https://www.mhsystem.org/health-library/con-20344525/
    Learn enough about sarcoma to make decisions about your care. Ask your doctor about your sarcoma, including your treatment options and, if you like, your prognosis. As you learn more about undifferentiated pleomorphic sarcoma, you may become more confident in making treatment decisions. […] Keeping your close relationships strong will help you deal with your diagnosis and care implications. Friends and family can provide the practical support youll need, such as helping take care of your home if youre in the hospital. And they can serve as emotional support when you feel overwhelmed by cancer. […] If your family doctor suspects you have undifferentiated pleomorphic sarcoma, youll likely be referred to a cancer doctor (oncologist) who specializes in sarcomas. Undifferentiated pleomorphic sarcoma is rare and often requires complex care. Its best treated by someone who has significant experience with it, which often means an academic or multispecialized cancer center.
  • #2 Soft Tissue Sarcoma Treatment | Sarcoma Care Team | Parkview Health
    https://www.parkview.com/medical-services/cancer/cancers-we-treat/soft-tissue-sarcoma
    Soft tissue sarcomas are a rare group of cancers arising from connective tissue such as muscle, fat, nerves, bone and vascular tissue, that can occur at any age. […] At Parkview Cancer Institute we have a dedicated Sarcoma Care Team including radiation oncology, medical oncology, interventional radiology, pathology, plastic surgery, nurse navigation, genetics, nutrition, spiritual support, and financial support, led by our orthopedic oncologic surgeon. […] To maximize accuracy of radiation and minimize associated harm, we utilize Intensity Modulated Radiation Therapy (IMRT), which has been demonstrated in studies to result in optimal local control rates for soft tissue sarcomas. […] During the surveillance period, patients undergo physical therapy, spiritual counseling, nutritional support, and financial support as needed, all of which is coordinated by our sarcoma nurse navigator.
  • #2 Sarcoma | MUSC Hollings Cancer Center
    https://hollingscancercenter.musc.edu/patient-care/cancer-types/sarcoma
    Our team includes fellowship-trained clinicians in orthopaedic oncology, surgical oncology, and medical oncology, all with a clinical focus on sarcoma patients. […] Our team of sarcoma specialists knows how important it is to offer you options when it comes to your treatment. Some of the resources available to you include: […] Our sarcoma nurse navigator, Melinda Walto, BSN, RN, will help you understand what to expect during treatment and answer questions you may have.
  • #2 Undifferentiated pleomorphic sarcoma | Health Library | Memorial Health System
    https://www.mhsystem.org/health-library/con-20344525/
    Treatment for undifferentiated pleomorphic sarcoma usually involves surgery to remove the cancer cells. Other options include radiation therapy and drug treatments (systemic therapies), such as chemotherapy, targeted therapy and immunotherapy. Which treatments are best for you will depend on the size and location of your cancer. […] When possible, doctors try to remove the sarcoma completely with surgery. The goal is to remove the cancer and a margin of healthy tissue around it with as minimal an impact as possible. […] When the cancer affects the arms and legs, surgeons prefer to use limb-sparing operations. However, in some cases it may be necessary to amputate the affected arm or leg. Other treatments, such as radiation therapy and chemotherapy, might be recommended before surgery to shrink a cancer so that its easier to remove without amputating the affected limb.
  • #2 Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Surgical Oncology Goals
    https://www.onclive.com/view/moving-the-needle-in-undifferentiated-pleomorphic-sarcoma-surgical-oncology-goals
    Once they’ve undergone their neoadjuvant therapy, we’re going to want to do a resection of the tumor that involves negative margins. What that means is we want to see on the pathology that there is normal tissue between the edge of the tumor and the edge of the specimen. […] Ideally, we’re getting at least a couple of mm, as wide a margin as possible. But when we’re performing limb salvage surgery, these tumors may be pressed up against a blood vessel or a nerve, so we may be taking a very minimal margin, or sometimes what some people call a planned positive margin, which is really when we’re resecting a thin layer, such as the adventitia off a vessel or the epineurium off a nerve, and that’s going to be our margin. […] At this point, most of the time we’re able to save someone’s arm or leg. […] For the most part, someone who specializes in sarcoma can save the person’s extremity the majority of the time. […] Even if the tumor involves certain blood vessels or certain nerves, there are methods to save the patient’s limb.
  • #2 Undifferentiated pleomorphic sarcoma | Health Library | Memorial Health System
    https://www.mhsystem.org/health-library/con-20344525/
    Radiation therapy uses high-powered beams of energy, such as X-rays or protons, to kill cancer cells. Radiation therapy can be given as: […] Chemotherapy is a drug treatment that uses chemicals to kill cancer cells. It can be administered by pill or through a vein (intravenously), or both. […] Chemotherapy is most often used to treat undifferentiated pleomorphic sarcoma that comes back after initial treatment or that spreads to other areas of the body. […] Immunotherapy uses your immune system to fight cancer. Your bodys disease-fighting immune system may not attack your cancer because the cancer cells produce proteins that help them hide. Immunotherapy works by interfering with that process. […] A diagnosis of cancer such as undifferentiated pleomorphic sarcoma can be overwhelming. With time youll find ways to cope with the distress and uncertainty of cancer. Until then, you may find it helps to:
  • #2 Undifferentiated pleomorphic sarcoma // Middlesex Health
    https://middlesexhealth.org/learning-center/diseases-and-conditions/undifferentiated-pleomorphic-sarcoma
    Radiation therapy uses high-powered beams of energy, such as X-rays or protons, to kill cancer cells. Radiation therapy can be given as: […] Chemotherapy is a drug treatment that uses chemicals to kill cancer cells. It can be administered by pill or through a vein (intravenously), or both. […] Chemotherapy is most often used to treat undifferentiated pleomorphic sarcoma that comes back after initial treatment or that spreads to other areas of the body. […] Immunotherapy uses your immune system to fight cancer. Your body’s disease-fighting immune system may not attack your cancer because the cancer cells produce proteins that help them hide. Immunotherapy works by interfering with that process. […] A diagnosis of cancer such as undifferentiated pleomorphic sarcoma can be overwhelming. With time you’ll find ways to cope with the distress and uncertainty of cancer. Until then, you may find it helps to:
  • #2 Sarcoma
    https://medschool.cuanschutz.edu/colorado-cancer-center/for-patients-families/cancers-we-treat/sarcoma
    Radiation therapy uses high-energy beams (such as x-rays) to destroy cancer cells. It is used most often for sarcomas of the arms and legs but may also be used for other sarcomas. Radiation may be given before sarcoma surgery (neoadjuvant radiation) to shrink tumors or after surgery (adjuvant radiation) to kill any remaining cancer cells. It is often given in combination with chemotherapy, which is known as chemoradiotherapy or chemoradiation. […] […] Chemotherapy is a drug treatment to kill cancer cells. Some types of sarcomas respond better to chemotherapy than others. Like radiation therapy, chemotherapy may be used before surgery to try to shrink the tumors or after surgery to kill any remaining cancer cells. […] […] Targeted therapies use drugs to inhibit the action of defective genes and slow or halt the growth and spread of sarcoma cancer cells while limiting harm to healthy cells.
  • #2 Pleomorphic Sarcoma of the Liver; To Cut or Not to Cut? | ACS
    https://www.facs.org/for-medical-professionals/news-publications/journals/case-reviews/issues/v1n3/dishong-pleomorphic/
    Prognosis of UPS is often poor regardless of intervention. […] Thus, due to the rapid growth of the mass in a relatively short amount of time, the failed nutritional optimization and increasing frequency of hospitalizations, it was unlikely that surgical resection (three months after presentation) would improve prognosis of the patient, but we hoped that it would improve the quality of her remaining days. […] In conclusion, for lesions larger than 10 cm, we would encourage a brief trial of nutritional adjuncts limited to no more than two weeks and if there are no objective signs of nutritional improvement, the decision to operate or not to operate should be finalized. […] Palliative surgery and care are important considerations for UPS.
  • #2 Undifferentiated pleomorphic sarcoma – Diagnosis and treatment – Mayo Clinic
    https://www.mayoclinic.org/diseases-conditions/undifferentiated-pleomorphic-sarcoma/diagnosis-treatment/drc-20389565
    Our caring team of Mayo Clinic experts can help you with your undifferentiated pleomorphic sarcoma-related health concerns […] Undifferentiated pleomorphic sarcoma is rare and often requires complex care. It’s best treated by someone who has significant experience with it, which often means an academic or multispecialized cancer center. […] Learn enough about sarcoma to make decisions about your care. Ask your doctor about your sarcoma, including your treatment options and, if you like, your prognosis. As you learn more about undifferentiated pleomorphic sarcoma, you may become more confident in making treatment decisions. […] Keeping your close relationships strong will help you deal with your diagnosis and care implications. Friends and family can provide the practical support you’ll need, such as helping take care of your home if you’re in the hospital. And they can serve as emotional support when you feel overwhelmed by cancer.